News
8h
Clinical Trials Arena on MSNMTPA’s Radicava shows long-term benefit in ALS trials
"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...
18h
Stockhead on MSNNeurizon’s ALS drug shows safety and extended survival in open-label extension study
Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.
Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
David Crean, Chief Business Officer at MediciNova (Nasdaq: MNOV), a late-stage, global biopharmaceutical company that is ...
• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results